[New strategies in therapy to roll back malaria].
Kaiser
A
A
Institut für Medizinische Parasitologie, Bonn. akaiser@parasit.meb.uni-bonn.de
Maier
W
W
D000962:Antimalarials / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D053626:Atovaquone; D004338:Drug Combinations; D018432:Drug Resistance, Multiple; D004359:Drug Therapy, Combination; D006801:Humans; D016778:Malaria, Falciparum / Q000188:drug therapy* / Q000517:prevention & control / Q000635:transmission; D008657:Metabolic Clearance Rate; D009285:Naphthoquinones / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D002727:Proguanil / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D012307:Risk Factors; D014195:Travel
D000962:Antimalarials; D004338:Drug Combinations; D009285:Naphthoquinones; C109496:atovaquone, proguanil drug combination; D002727:Proguanil; D053626:Atovaquone